The evolution of Magtrace: Breaking down the data behind the world’s most versatile lymphatic tracer
Adopting new technologies can feel like taking a step into the unknown. Fortunately, Magtrace has built a comprehensive clinical data library over the last decade that demonstrates why it offers a unique new approach to axilla management.
Speaking at the Transatlantic Breast Cancer Collaborative meeting, Kandace McGuire MD drew upon data from over 100 studies, featuring 8,000+ patients, to summarise the key studies that show Magtrace to be non-inferior to the “gold standard” for SLNB — as well as provide opportunities to de-escalate surgery through groundbreaking new techniques.
Watch as Dr McGuire discusses:
- The wealth of Magtrace data, proving it’s non-inferiority to the ‘gold standard’ for SLNB.
- How multiple studies show that reducing the injection volume to 1ml* demonstrates equivalent performance and can minimize temporary skin discoloration.
- The MagTotal study demonstrates that Magtrace can be used to great effect alongside Magseed, with a very low re-excision rate of less than 3% and high clinical satisfaction.
- Revolutionary techniques such as MagUS (2021), which could offer a minimally invasive axillary mapping technique and has been shown to perform comparatively to baseline axillary ultrasound.
*Indication varies between countries. Please check your IFU for injection guidance.